HOME >> MEDICINE >> NEWS
NIAID Ebola vaccine enters human trial

searchers will also examine the volunteers' blood to look for signs of immune system reaction to the vaccine. Ultimately, the scientists envision this vaccine as the first in a two-stage vaccination strategy called prime-boost: after "priming" with the DNA vaccine, the immune system response is "boosted," or augmented, by a second inoculation with modified, non-disease-causing cold viruses that make selected Ebola proteins. The booster essentially sets the immune system on alert against future infection by Ebola virus.

In August, Dr. Nabel and his colleagues reported using the booster shot to quickly and completely protect monkeys against Ebola. A fast-acting vaccine would be of great use during an outbreak of Ebola. The full prime-boost strategy, which uses the DNA vaccine being tested in this study, elicits a stronger immune response and is important to pursue for individuals at high risk, such as health care workers. Dr. Nabel says that expanded human trials of Ebola vaccines using the prime-boost strategy could begin by 2005.


'"/>

Contact: Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
18-Nov-2003


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID Ebola vaccine enters human trial

(Date:7/25/2014)... (PRWEB) July 25, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Ibuprofen and Oxcarbazepine ... that one lot of Ibuprofen and one lot of Oxcarbazepine ... due to mislabeled packaging. Oxcarbazepine is used for the treatment ... , The reason for the recall is that Lot ...
(Date:7/25/2014)... July 25, 2014 Parker Waichman LLP, ... of consumers comments on a recent tobacco lawsuit in ... smoker $23.6 billion in punitive damages. Cynthia Robinson brought ... cigarettes. The case is Cynthia Robinson v. R.J. Reynolds ... Florida First Circuit Court, Escambia County, Florida; Case Number ...
(Date:7/25/2014)... Drexel University College of Medicine is pleased ... been appointed vice dean for education, effective October 1, 2014. ... Medical College, where she is currently chair of the Department ... of medicine. , As a member of the senior ... major role in many aspects of the development of the ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
(Date:7/25/2014)... 25, 2014 The new report ... Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, ... Geography - Global Trends & Forecasts to 2019", ... of the global Carbohydrase market with analysis of ... is segmented and values are forecasted on the ...
Breaking Medicine News(10 mins):Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... July 24, 2014 Amgen (NASDAQ: AMGN ... financial results on Tuesday, July 29, 2014, after the close ... by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, ... Live audio of the conference call will be simultaneously broadcast ...
(Date:7/24/2014)... British Columbia and MENLO PARK, Calif. ... Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today that ... company,s fiscal year from December 31 to June 30. Accordingly, ... September 30, 2014. Jeffrey Bacha , president ... end is an important step in achieving our goal of ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
Cached News: